Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission (EC) has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.
In 2004, a form of cancer known as neuroblastoma claimed the life of Alexandra (Alex) Scott, a little girl who gained national attention for using her lemonade stand to raise money for cancer research. Now, the organization established in her memory, the Alex's Lemonade Stand Foundation (ALSF), has awarded University of Maryland (UMD) A. James Clark School of Engineering Assistant Professor Christopher M. Jewell a three-year, $375,000 research grant to support the pre-clinical development of a cancer vaccine technology that could give children like Alex a better chance to have a long and healthy life.
Vaccines combat diseases and protect populations from outbreaks, but the life-saving technology leaves room for improvement. Vaccines usually are made en masse in centralized locations far removed from where they will be used. They are expensive to ship and keep refrigerated and they tend to have short shelf lives.
Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the Company’s proprietary Mucus Penetrating Particle (MPP) technology, announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to initiate a Phase 3 clinical program with its MPP-formulated loteprednol etabonate ophthalmic nano-suspension product (LE-MPP) for the treatment of post-operative inflammation and pain following cataract surgery.
Researchers have developed a technique for creating nanoparticles that carry two different cancer-killing drugs into the body and deliver those drugs to separate parts of the cancer cell where they will be most effective. The technique was developed by researchers at North Carolina State University and the University of North Carolina at Chapel Hill.
Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases. The partnership was established to support Astellas' goal of building a global vaccine franchise and launched its first company, RSV Corporation (RSVC), in December 2013.
Tauriga Sciences, Inc. or ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced that it has a received a comprehensive update from Immunovative Therapies Ltd. ("ITL") highlighting some potentially positive developments.
European Research Council (ERC) provides funding for the world's top researchers and their groundbreaking projects. The funding programme has received 3680 applications from across Europe this year, and the project of Prof. Özgür Barýþ Akan from Koç University's Department of Electrical and Electronics Engineering has qualified for the grant.
A novel breast-cancer therapy that partially reverses the cancerous state in cultured breast tumor cells and prevents cancer development in mice, could one day provide a new way to treat early stages of the disease without resorting to surgery, chemotherapy or radiation, a multi-institutional team led by researchers from the Wyss Institute of Biologically Inspired Engineering at Harvard University reported January 1 in Science Translational Medicine.
Rice University researchers have developed a noninvasive technology that accurately detects low levels of malaria infection through the skin in seconds with a laser scanner. The “vapor nanobubble” technology requires no dyes or diagnostic chemicals, and there is no need to draw blood.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.